What is there not to like? Sofdra is just the first of many products to come.
"BOT is projecting market share of 30% for diagnosed patients and targeting undiagnosed patients through digital and telemedicine efforts.Focus is on the US market due to high pharmaceutical spend. But exploring partnerships for other markets (e.g., Japan, Australia, Europe).The team behind the company appears to have serious form, with people like Vince Ippolito (Executive Chairman) and Howie McKibbon (CEO) demonstrating successful track records in dermatology product launches and exits.Execution on current plans while exploring additional product opportunities."
BOT - Anything but charting, page-9912
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $642.5M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $1.358M | 3.872M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1354176 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 82352 | 4 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |